Piper Sandler Maintains Overweight on Cogent Biosciences, Raises Price Target to $55
Benzinga Newsdesk 2 months ago
Analyst RatingsNewsPrice Target
Piper Sandler analyst Christopher Raymond maintains Cogent Biosciences (NASDAQ:COGT) with a Overweight and raises the price target from $52 to $55.
Piper Sandler analyst Christopher Raymond maintains Cogent Biosciences (NASDAQ:COGT) with a Overweight and raises the price target from $52 to $55.